SCHEMBL23510481

SCHEMBL23510481

O=C1NC(SCc2ccccc2)=N/C1=C\c1ccc2[nH]cnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.48
▸ GPR18 Q14330 3/20 0.48
▸ DYRK3 O43781 6/20 0.43
▸ DYRK1A Q13627 6/20 0.43
▸ DYRK2 Q92630 6/20 0.43
▸ DYRK1B Q9Y463 6/20 0.43
▸ PIM1 P11309 5/20 0.43
▸ CSNK2A2 P19784 5/20 0.43
▸ CSNK2B P67870 5/20 0.43
▸ CSNK2A1 P68400 5/20 0.43
▸ CSNK2A3 Q8NEV1 5/20 0.43
▸ ABL1 P00519 1/20 0.42
▸ RIN1 Q13671 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ MAPT P10636 4/20 0.39
▸ GAA P10253 1/20 0.39
▸ CNR1 P21554 3/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ QPCT Q16769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26095300 0.86 KDM4E (0.60) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL30494246 0.86 KDM4E (0.60) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL30494355 0.82 MAPT (0.58) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL26091653 0.82 MAPT (0.58) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL29899881 0.78 DYRK1A (0.45) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL28842915 0.78 DYRK1A (0.45) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL24904253 0.78 DYRK1A (0.45) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL24904266 0.77 KDM4E (0.60) KDM4EGPR18DYRK3DYRK1ADYRK2
SCHEMBL24904303 0.76 DYRK1A (0.64) DYRK3DYRK1ADYRK2DYRK1BPIM1
SCHEMBL28842923 0.76 DYRK1A (0.64) DYRK3DYRK1ADYRK2DYRK1BPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 — — US disclosed
WO-2021115489-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed
WO-2021114314-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 KDM4E 3429/4885GPR18 2045/4885DYRK3 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback